Published 5 days ago • loading... • Updated 5 days ago

Fine, Kaplan and Black, R.P.C. Announce Class Action Lawsuits on Behalf of Those Who Paid and/or Reimbursed for GENERIC CLOBETASOL between September 1, 2014 and December 31, 2018 or GENERIC CLOMIPRAMINE between August 1, 2013 and December 31, 2018

Fine, Kaplan and Black, R.P.C. Announced ongoing class action lawsuits on May 6, 2025, in Philadelphia concerning generic Clobetasol and Clomipramine purchases.
The lawsuits arose because Third-Party Payers, acting as End-Payers, claim generic drug makers violated antitrust and consumer protection laws causing overpayments from 2013 to 2018.
Defendants include Actavis, Akorn, Sandoz, Taro, Wockhardt, and Mylan, and the court certified these as class actions with a trial set for August 2025.
The EPPs have agreed to settle with Sandoz for $275 million, subject to court approval, which could result in Sandoz being removed from all associated lawsuits.
Participating class members need not pay attorney fees, must submit exclusion requests by July 5, 2025, and will be bound by court rulings while receiving possible settlement proceeds.

Insights by Ground AI

Does this summary seem wrong?